



162162



G00002

ABSTRACT

A drug for preventing vascular restenosis comprises a compound that inactivates $\alpha 1$ -protease inhibitor and $\alpha 2$ -
5 macroglobulin as active constituents, which are associated with occurrence of vascular restenosis after coronary artery intervention. Preferably, the drug is coated on a surface of an implantable intravascular device and locally administered to the affected area by application of the implantable intravascular device to a
10 narrowed area.